Article Data

  • Views 1252
  • Dowloads 104

Editorials

Open Access

A case of bilateral ovarian synchronous tumors (left ovarian serous papillary adenocarcinoma and right

ovarian malignant mixed Müllerian tumor)

  • M.J. Song1
  • C.W. Lee1
  • K.J. Seo2
  • J.A. Kim2
  • J.S. Park1
  • S.Y. Hur1,*,

1Department of Obstetrics and Gynecology, School of Medicine, Catholic University, Seoul St. Mary’s Hospital, Seoul, South Korea

2Department of Pathology, School of Medicine, Catholic University, Bucheon St. Mary’s Hospital, Bucheon, Gyeonggi-Do, Seoul, South Korea

DOI: 10.12892/ejgo201102234 Vol.32,Issue 2,March 2011 pp.234-236

Published: 10 March 2011

*Corresponding Author(s): S.Y. Hur E-mail: hursy@catholic.ac.kr

Abstract

Synchronous bilateral ovarian cancer is extremely rare and there is no established guideline for management. A case of a 58-year-old multiparous woman with bilateral ovarian synchronous malignant tumors is presented. The clinical consideration and treatment of related cases are discussed.

Keywords

Ovarian synchronous tumors; Serous papillary adenocarcinoma; Malignant mixed Müllerian tumor

Cite and Share

M.J. Song,C.W. Lee,K.J. Seo,J.A. Kim,J.S. Park,S.Y. Hur. A case of bilateral ovarian synchronous tumors (left ovarian serous papillary adenocarcinoma and rightovarian malignant mixed Müllerian tumor). European Journal of Gynaecological Oncology. 2011. 32(2);234-236.

References

[1] Eisner R.F., Nieberg R.K., Berek J.S.: “Synchronous primary neoplasms of the female reproductive tract”. Gynecol. Oncol., 1989, 33, 335.

[2] Eifel P., Hendrickson M., Ross J., Ballon S., Mantinez A., Kempson R.: “Simultaneous presentation of carcinoma involving the ovary and endometrium”. Cancer, 1982, 50, 163.

[3] Dictor M.: “Malignant mixed mesodermal tumor of the ovary: A report of 22 cases”. Obstet. Gynecol., 1985, 65, 720.

[4] Hanjani P., Peterson R.O., Lipton S.E., Nolte S.A.: “Malignant mixed mesodermal tumors and carcinosarcoma of the ovary: Report of eight cases and review of the literature”. Obstet. Gynecol. Surv., 1983, 38, 537.

[5] Pfeiffer P., Hardt-Madsen M., Rex S., Holund B., Bertelsen K.: “Malignant mixed müllerian tumors of the ovary. Report of 13 cases”. Acta Obstet. Gynecol. Scand., 1991, 70, 79.

[6] Le T., Krepart G.V., Lotocki R.J., Heywood M.S.: “Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience”. Gynecol. Oncol., 1997, 65, 237.

[7] Moritani S., Moriya T., Kushima R., Sugihara H., Harada M., Hattori T.: “Ovarian carcinoma recurring as carcinosarcoma”. Pathol. Int., 2001, 51, 380.

[8] Mok J.E., Kim Y.M., Jung M.H., Kim K.R., Kim D.Y., Kim J.H. et al.: “Malignant mixed müllerian tumors of the ovary: experience with cytoreductive surgery and platinum-based combination chemotherapy”. Int. J. Gynecol. Cancer, 2006, 16, 101.

[9] Gallardo A., Matias-Guiu X., Lagarda H., Catasus L., Bussaglia E., Gras E. et al.: “Malignant müllerian mixed tumor arising from ovarian serous carcinoma: a clinicopathologic and molecular study of two cases”. Int. J. Gynecol. Pathol., 2002, 21, 268.

[10] Masuda A., Takeda A., Fukami H., Yamada C., Matsuyama M.: “Characteristics of cell lines established from a mixed mesodermal tumor of the human ovary”. Cancer, 1987, 60, 2696. tumor of the human ovary”. Cancer, 1987, 60, 2696.

[11] Scully R.E., Young R.H., Clement P.B.: “Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament”. In: Rosai J. (ed.). “Atlas of Tumor Pathology”, 3rd series, fascicle 23. Washington, D.C.: Armed Forces Institute of Pathology 1998, 128.

[12] Dehner L.P., Norris H.J., Taylor H.B.: “Carcinosarcomas and mixed mesodermal tumors of the ovary”. Cancer, 1971, 27, 207.

[13] FIGO Cancer Committee. Staging announcement. Gynecol. Oncol., 1986, 25, 83.

[14] Muntz H.G., Jones M.A., Goff A., Fuller A.F., Jr., Nikrui N., Rice L.W., Tarrazza H.M.: “Malignant mixed müllerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy”. Cancer, 1995, 76, 1209.

[15] Sood A.K., Sorosky J.I., Gelder M.S., Buller R.E., Anderson B., Wilkenson E.J. et al.: “Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction”. Cancer, 1998, 82, 1731.

[16] Sutton G.P., Blessing J.A., Homesley H.D., Malfetano J.H.: “A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1994, 53, 24.

[17] Plaxe S.C., Dottino P.R., Goodman H.M., Deligdisch L., Idelson M., Cohen C.J.: “Clinical features of advanced ovarian mixed mesodermal tumors and treatment with doxorubicin and cis platinum based chemotherapy”. Gynecol. Oncol., 1990, 37, 244.

[18] Baker T.R., Piver M.S., Caglar H., Piedmonte M.: “Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary”. Am. J. Clin. Oncol., 1991, 9, 246.

[19] Bicher A., Levenback C., Silva E.G., Burke T.W., Morris M., Gershenson D.M.: “Ovarian malignant mixed müllerian tumors treated with platinum-based chemotherapy”. Obstet. Gynecol., 1995, 85, 735.

Submission Turnaround Time

Top